Skip to main content
Natera, Inc. logo

Natera, Inc. — Investor Relations & Filings

Ticker · NTRA ISIN · US6323071042 LEI · 529900CQ3OZ0A0VYVU59 US Human health and social work activities
Open in API
Filings indexed 1,586 across all filing types
Latest filing 2016-11-15 Director's Dealing
Country US United States of America
Listing US NTRA

About Natera, Inc.

https://www.natera.com/

Natera, Inc. is a diagnostics company specializing in cell-free DNA (cfDNA) testing. The company develops and commercializes non-invasive tests focused on three primary areas: women's health, oncology, and organ health. In women's health, its products include the Panorama non-invasive prenatal test (NIPT) and the Horizon carrier screening test to assess genetic risks. The oncology portfolio features Signatera, a personalized molecular residual disease (MRD) test used to monitor cancer recurrence and treatment response. For organ health, its tests are designed to detect early signs of transplant rejection. Natera's technology aims to provide actionable information for personalized medical care, supported by extensive clinical validation through numerous peer-reviewed studies.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2016-11-15 English
10-Q Filing
Interim / Quarterly Report Q3 2016
2016-11-14 English
S-3 Filing
Regulatory Filings Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Natera, Inc. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale to the public. The text includes details about the types of securities to be registered (common stock, preferred stock, debt securities, warrants, units), the registration fee, and disclaimers about the prospectus. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to capital raising but is not a direct capital/financing update or earnings release. The document is a formal SEC filing for registration of securities, which fits best under the category of Regulatory Filings (RNS) as it does not fit the more specific categories like Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA) which are typically announcements rather than registration statements. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement of a report. Therefore, the best classification is Regulatory Filings (RNS).
2016-11-14 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release announcing third quarter results. The document itself does not contain detailed financial statements or comprehensive analysis but rather furnishes a press release as an exhibit. The length is 3373 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such filings that announce earnings results but do not contain the full financial data or detailed analysis are classified as Earnings Release (ER).
2016-11-09 English
4 Filing
Director's Dealing
2016-11-04 English
4 Filing
Director's Dealing
2016-11-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.